Skip to main content

The effect of four different types of diet on the bioavailability of loracarbef


This randomized open-label single-dose crossover pharmacokinetic study was carried out to assess the effect of different diets on the bioavailability of loracarbef in 24 healthy male volunteers. A single dose of loracarbef in 200-mg tablet form was administered at 5 different times: after overnight fasting, after two vegetarian (high-fat and low-fat) diets, and following two non-vegetarian (high-fat and low-fat) diets. Serial blood samples were collected up to 10 h post-dose. Serum loracarbef concentrations were determined by a validated high performance liquid chromatographic (HPLC) method. Area under curve (AUC) values were significantly affected only by non-vegetarian diets; however the time to reach maximum serum concentration (Tmax) was prolonged and the maximum serum concentration (Cmax) was decreased by all types of meals. The non-vegetarian diets affected the rate of absorption of loracarbef more than the vegetarian diets. The lowest decrease in Cmax was produced by the high-fat vegetarian diet, while the maximum was produced by the low-fat non-vegetarian diet. The results of this study indicate that while the rate of loracarbef absorption is significantly decreased by all diets, the extent of absorption is only reduced significantly by the non-vegetarian diets. The rate of elimination (kel) was not found to be significantly decreased by any of the diets. As compared to the high-fat non-vegetarian diet, the time beyond minimum inhibitory concentration (MIC90) concentration was significantly increased by the high-fat vegetarian diet. The implications of these findings for the large Indian vegetarian population are considerable.

This is a preview of subscription content, access via your institution.


  1. 1.

    Pasini C.E., Indelicato J.M. (1992): Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic. Pharm. Res., 9, 250–254.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Therasse D.G. (1992): The safety profile of loracarbef: clinical trials in respiratory, skin and urinary tract infections. Am. J. Med., S6A, 20S-25S.

    Article  Google Scholar 

  3. 3.

    Brogden R.N., McTavish D. (1993): Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 45, 716–736.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Gauthier I., Malone M. (1998): Drug food interactions in hospitalized patients. Methods of prevention. Drug Saf., 18, 383–393

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Scmidt L.E., Dalhoff K. (2002): Food-drug interactions. Drugs, 62, 1481–1502.

    Article  Google Scholar 

  6. 6.

    Glynne A., Goulborn A., Ryder R. (1978): A human pharmacology study of cefaclor. Antimicrob. Agents Chemother., 4, 343–348.

    Article  CAS  Google Scholar 

  7. 7.

    Haginaka J., Yamaoka K., Kagagama T., Nishimura Y., Uno T. (1979): Evaluation of food ingestion on bioavailability of cephalexin by moment analysis. Chem. Pharm. Bull., 27, 3156–3159.

    CAS  PubMed  Google Scholar 

  8. 8.

    Singh B.N. (1999): Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet., 37, 213–255.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Lode H., Stahlmann R., Koeppe P. (1979): Comparative pharmacokinetics of cephalexin, loracarbef, Cefadroxil, and CGP 9000. Antimicrob. Agents Chemother., 16, 1–6.

    CAS  PubMed  Google Scholar 

  10. 10.

    Barbhaiya R.H., Gleason C.R., Shyu W.C., Pittman K.A. (1990): Comparison of the effects of food on the pharmacokinetics of cefprozil and loracarbef. Antimicrob. Agents Chemother., 34, 1210–1213.

    CAS  PubMed  Google Scholar 

  11. 11.

    McCracken G.H. Jr., Ginsburg C.M., Clahsen J.C., Thomas M.L. (1978): Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. Pediatrics, 62, 738–743.

    PubMed  Google Scholar 

  12. 12.

    Hodges G.R., Liu C., Hinthorn D.R., Harms J.L., Dworzack D.L. (1978): Pharmacological evaluation of loracarbef in volunteers. Antimicrob. Agents Chemother., 14, 454–456.

    CAS  PubMed  Google Scholar 

  13. 13.

    Finn A., Straughn A., Meyer M. (1987): Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm. Drug Dispos., 8, 519–526.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Williams P.E., Harding S.M. (1984): The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J. Antimicrob. Chemother., 13, 191–196.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    ( /guidance/index.htm)

  16. 16.

    Kovach P.M., Lantz R.J. (1991): High Performance Liquid Chromatography determination of loracarbef, a potential metabolite, cefaclor and cephalexin in human plasma, serum and urine. J. Chromatogr., 567, 129–139.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Brogden R.N., Mc Tavish D. (1993): A review of loracarbef’s antimicrobial activity, pharmcokinetic properties and therapeutic efficacy. Adis International Ltd. Auckland, New Zealand, 45, 716–736.

    Google Scholar 

  18. 18.

    Roller S., Lode H., Stelzer I. (1992): Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur. J. Clin. Micro. Infect. Dis., 11, 851–855.

    Article  CAS  Google Scholar 

  19. 19.

    DeSante K.A., Zeckel M.L. (1992): Pharmacokinetic profile of loracarbef. Am. J. Med., S6A, 16S-19S.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to P. L. Sharma.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bapujee, A.T., Singh, T., Ahmed, T. et al. The effect of four different types of diet on the bioavailability of loracarbef. Eur. J. Drug Metabol. Pharmacokinet. 32, 205–211 (2007).

Download citation

Key words

  • Diet
  • bioavailabilty
  • loracarbef
  • pharmacokinetics